SS Innovations International Inc. (NASDAQ: SSII) has facilitated the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, according to a company announcement. The program utilizes the SSi Mantra 3.0 surgical robotic system and represents a milestone in the adoption of robotic-assisted cardiac care in South Asia.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration underscores the company's commitment to advancing surgical robotics globally and training local surgeons in advanced techniques.
Kings Hospital has completed more than 25 robotic procedures in just three weeks, according to a recent company video describing the program's early activity. This rapid uptake demonstrates the potential for robotic surgery to enhance patient outcomes and hospital efficiency in the region.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter, signaling a steady expansion of its global installed base. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528, pointing to rising utilization of the company's systems. These figures indicate growing acceptance of robotic-assisted surgery and the company's ability to capitalize on that trend.
The next major corporate milestone for SS Innovations is regulatory expansion, with the company pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open doors to two of the largest healthcare markets in the world, potentially accelerating revenue growth and further validating the technology's safety and efficacy.
For readers, this news highlights the increasing globalization of advanced medical technology and the potential for improved access to minimally invasive cardiac procedures. The successful implementation in Sri Lanka could serve as a model for other emerging markets, where robotic surgery can address unmet clinical needs and enhance surgical precision.
Investors and industry observers may view this development as a positive indicator of SS Innovations' strategic execution and market penetration. The company's focus on regulatory approvals in the U.S. and Europe could be a catalyst for future stock performance, as these markets represent significant opportunities for expansion.
The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
For more information, please visit https://www.TechMediaWire.com. Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer.
